Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies

Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies

Mona Noori Koopaei1, Rassoul Dinarvand1,2, Mohsen Amini3, Hojatollah Rabbani4, Shaghayegh Emami4, Seyed Nasser Ostad5, Fatemeh Atyabi1,21Novel Drug Delivery Laboratory, Faculty of Pharmacy, 2Nanotechnology Research Center, 3Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of...

Full description

Bibliographic Details
Main Authors:	Noori Koopaei M, Dinarv, R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-09-01
Series:	International Journal of Nanomedicine
Online Access:	http://www.dovepress.com/docetaxel-immunonanocarriers-as-targeted-delivery-systems-for-her2-pos-a8243

Similar Items

Chitosan&ndash;Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study
by: Ostad SN, et al.
Published: (2012-04-01)

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
by: Yousefpour P, et al.
Published: (2011-09-01)

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
by: Rouhani H, et al.
Published: (2011-04-01)

Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells
by: Talaei F, et al.
Published: (2011-09-01)

Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation
by: Shahrooz Saremi, et al.
Published: (2011-01-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy
by: Vakhshiteh F, et al.
Published: (2019-04-01)

Polyanionic carbohydrate doxorubicin&ndash;dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations
by: Yousefpour P, et al.
Published: (2011-07-01)

Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
by: Mohamed A. Ibrahim, et al.
Published: (2019-01-01)

Inclusion Complex of Docetaxel with Sulfobutyl Ether β-Cyclodextrin: Preparation, In Vitro Cytotoxicity and In Vivo Safety
by: Lili Ren, et al.
Published: (2020-10-01)

Size-Controlled Preparation of Docetaxel- and Curcumin-Loaded Nanoemulsions for Potential Pulmonary Delivery
by: Azren Aida Asmawi, et al.
Published: (2023-02-01)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
by: Binwei Lin MM, et al.
Published: (2023-11-01)

The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
by: Reem T. Attia, et al.
Published: (2016-06-01)

Chitosomes Loaded with Docetaxel as a Promising Drug Delivery System to Laryngeal Cancer Cells: An In Vitro Cytotoxic Study
by: Christian R. Moya-Garcia, et al.
Published: (2023-06-01)

Targeted Delivery of Doxorubicin Utilizing Chitosan Nanoparticles Surface Functionalized with Anti Her2 Trastuzumab [Corrigendum]
by: Yousefpour P, et al.
Published: (2022-10-01)

In vitro evaluation of mutagenicity and cytotoxicity of four root canal sealers
by: Zarrabian M., et al.
Published: (2007-07-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Targeted delivery of doxorubicin to HER2 positive tumor models
by: Gomari H, et al.
Published: (2019-07-01)

Formulation of docetaxel using prodrugs for intravenous delivery
by: Chang-Gu Keum, et al.
Published: (2012-01-01)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
by: Ashley M. Hopkins, et al.
Published: (2019-08-01)

Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
by: Yabing Zheng, et al.
Published: (2023-12-01)

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
by: Dan Liu, et al.
Published: (2023-05-01)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
by: Andrea Rocca, et al.
Published: (2021-02-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

Cytotoxic effect of a dentin bonding agent: AdheSE
by: Banava S., et al.
Published: (2007-05-01)

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells
by: Naime Majidi Zolbanin, et al.
Published: (2018-08-01)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
by: Gomari H, et al.
Published: (2019-09-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
by: Jiong Wu, et al.
Published: (2022-12-01)

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
by: Sapino Anna, et al.
Published: (2010-02-01)

Nano-interventions for the drug delivery of docetaxel to cancer cells
by: Nishtha Chaurawal, et al.
Published: (2023-06-01)

Cytotoxicity of Two Species of Glaucium from Iran
by: F Hadjiakhoondi, et al.
Published: (2013-02-01)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
by: Irin Tanaudommongkon, et al.
Published: (2020-07-01)

Effect of surface ligand density on cytotoxicity and pharmacokinetic profile of docetaxel loaded liposomes
by: Chun Chu, et al.
Published: (2016-10-01)

Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy
by: Fakhrossadat Emami, et al.
Published: (2023-09-01)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
by: Haoqi Wang, et al.
Published: (2022-07-01)

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy
by: Feng QZ, et al.
Published: (2021-10-01)

Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method
by: Jafarzadeh Kashi TS, et al.
Published: (2012-01-01)

Glucose-Modified Zein Nanoparticles Enhance Oral Delivery of Docetaxel
by: Yabing Xing, et al.
Published: (2022-06-01)

Design and Synthesis of Amphiphilic Graft Polyphosphazene Micelles for Docetaxel Delivery
by: Diana Serbezeanu, et al.
Published: (2023-05-01)